The pan-Canadian Oncology Drug Review (pCODR) transferred to CADTH on April 1, 2014. The key reason for the transfer was to further consolidate policy direction across different drug programs, and to improve the pCODR governance structure to ensure its long-term viability and sustainability. This direction was supported by health ministries and cancer agencies across the country.pCODR remains well-respected in the cancer and drug review communities. Its people, processes, and expertise are valued by jurisdictions, health care providers, and patients for providing quality evidence to decision-makers in support of drug funding decisions.

The transfer of pCODR to CADTH is occurring in two phases:

Phase 1 (effective April 1, 2014) —

• pCODR transfers to CADTH; staff, processes, funding, and expertise remain intact as a program, with a continued physical location in Toronto, Ontario, under the governance of CADTH.

Phase 2 (to commence April 2015) —

• Exploration of better alignment of pCODR and CADTH Common Drug Review evaluation criteria.
• Build upon the best practices of both review processes.

In the spirit of how pCODR and CADTH engage its stakeholders, the broader cancer community — including cancer agencies, patient groups, and industry — will be engaged at various points during the transfer.

pCODR and CADTH have been working together since the inception of pCODR in 2010. This transfer enables an even more collaborative relationship in the delivery of high-quality drug review processes for all Canadians.

For more details, go to: www.pCODR.ca